Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial
- 3.3k Downloads
Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which includes numbness, tingling, pain, cold sensitivity, and motor impairment in the hands and feet. CIPN is a dose-limiting toxicity, potentially increasing mortality. There are no FDA-approved drugs to treat CIPN, and behavioral interventions such as exercise are promising yet understudied. This secondary analysis of our nationwide phase III randomized controlled trial of exercise for fatigue examines (1) effects of exercise on CIPN symptoms, (2) factors that predict CIPN symptoms, and (3) factors that moderate effects of exercise on CIPN symptoms.
Cancer patients (N = 355, 56 ± 11 years, 93% female, 79% breast cancer) receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy were randomized to chemotherapy or chemotherapy plus Exercise for Cancer Patients (EXCAP©®). EXCAP is a standardized, individualized, moderate-intensity, home-based, six-week progressive walking and resistance exercise program. Patients reported CIPN symptoms of numbness and tingling and hot/coldness in hands/feet (0–10 scales) pre- and post-intervention. We explored baseline neuropathy, sex, age, body mass index, cancer stage, and cancer type as possible factors associated with CIPN symptoms and exercise effectiveness.
Exercise reduced CIPN symptoms of hot/coldness in hands/feet (−0.46 units, p = 0.045) and numbness and tingling (− 0.42 units, p = 0.061) compared to the control. Exercise reduced CIPN symptoms more for patients who were older (p = 0.086), male (p = 0.028), or had breast cancer (p = 0.076).
Exercise appears to reduce CIPN symptoms in patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy. Clinicians should consider prescribing exercise for these patients.
KeywordsCIPN Exercise Neuropathy
The authors would like to thank Drs. Susan Rosenthal and Amber Kleckner for their support on this project. We extend special thanks to the cancer patients, as well as the research staff in the University of Rochester Cancer Center NCORP Research Base at each of the NCI NCORP affiliates who recruited and followed participants in this study. We also thank the staff of the PEAK Human Performance Laboratory and the Cancer Control Psychoneuroimmunology Laboratory. We thank the National Cancer Institute and the Division of Cancer Prevention for their funding support of this project.
Funding was provided by the National Cancer Institute, including funds from NCORP (formerly CCOP) parent grant U10 CA037420, NCORP (formerly CCOP) supplement U10 CA037420, and R25 CA102618.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020 CrossRefPubMedGoogle Scholar
- 2.Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lanteri-Minet M, Grant R, Huddart R, Moynihan C, Maher J, Lucey R, E.Q.o.L. Group (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139. https://doi.org/10.1016/j.ejca.2005.02.012 CrossRefPubMedGoogle Scholar
- 11.Costigan M, Scholz J, Woolf CJ (2009) Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 32(1):1–32. https://doi.org/10.1146/annurev.neuro.051508.135531 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL, O. American Society of Clinical (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967. https://doi.org/10.1200/JCO.2013.54.0914 CrossRefPubMedGoogle Scholar
- 15.Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, O. Alliance for Clinical Trials in (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–1367. https://doi.org/10.1001/jama.2013.2813 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Tham A, Jonsson U, Andersson G, Soderlund A, Allard P, Bertilsson G (2016) Efficacy and tolerability of antidepressants in people aged 65 years or older with major depressive disorder—a systematic review and a meta-analysis. J Affect Disord 205:1–12. https://doi.org/10.1016/j.jad.2016.06.013 CrossRefPubMedGoogle Scholar
- 18.Mols F, Beijers AJ, Vreugdenhil G, Verhulst A, Schep G, Husson O (2015) Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv 9(3):512–522. https://doi.org/10.1007/s11764-015-0427-1 CrossRefPubMedGoogle Scholar
- 19.Stevinson C, Steed H, Faught W, Tonkin K, Vallance JK, Ladha AB, Schepansky A, Capstick V, Courneya KS (2009) Physical activity in ovarian cancer survivors: associations with fatigue, sleep, and psychosocial functioning. Int J Gynecol Cancer 19(1):73–78. https://doi.org/10.1111/IGC.0b013e31819902ec CrossRefPubMedGoogle Scholar
- 20.Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Vallerand JR, Adams SC, Proulx C, Dolan LB, Wooding E, Segal RJ (2014) Subgroup effects in a randomised trial of different types and doses of exercise during breast cancer chemotherapy. Br J Cancer 111(9):1718–1725. https://doi.org/10.1038/bjc.2014.466 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Streckmann F, Kneis S, Leifert JA, Baumann FT, Kleber M, Ihorst G, Herich L, Grussinger V, Gollhofer A, Bertz H (2014) Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol 25(2):493–499. https://doi.org/10.1093/annonc/mdt568 CrossRefPubMedGoogle Scholar
- 22.Zimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W, Rudolph R, Streckmann F, Baumann FT (2017) Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support Care Cancer. https://doi.org/10.1007/s00520-017-3875-5
- 28.American College of Sports Medicine (2010) ACSM’s guidelines for exercise testing and prescription. Lippincott, Williams, & Wilkins, BaltimoreGoogle Scholar
- 29.Mendoza TR, Zhao F, Cleeland CS, Wagner LI, Patrick-Miller LJ, Fisch MJ (2013) The validity and utility of the M. D. Anderson symptom inventory in patients with breast cancer: evidence from the symptom outcomes and practice patterns data from the eastern cooperative oncology group. Clin Breast Cancer 13(5):325–334. https://doi.org/10.1016/j.clbc.2013.02.014 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159(2):327–333. https://doi.org/10.1007/s10549-016-3939-0 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, ViennaGoogle Scholar
- 32.Mustian KM, Sprod LK, Janelsins M, Peppone LJ, Palesh OG, Chandwani K, Reddy PS, Melnik MK, Heckler C, Morrow GR (2013) Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol 31(26):3233–3241. https://doi.org/10.1200/JCO.2012.43.7707 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Yoshikawa T, Takano M, Miyamoto M, Yajima I, Shimizu Y, Aizawa Y, Suguchi Y, Moriiwa M, Aoyama T, Soyama H, Goto T, Hirata J, Suzuki A, Sasa H, Nagaoka I, Tsuda H, Furuya K (2017) Psoas muscle volume as a predictor of peripheral neurotoxicity induced by primary chemotherapy in ovarian cancers. Cancer Chemother Pharmacol 80:555. https://doi.org/10.1007/s00280-017-3395-5
- 35.Kleckner IR, Zhang J, Touroutoglou A, Chanes L, Xia C, Simmons WK, Quigley KS, Dickerson BC, Barrett LF (2017) Evidence for a Large-Scale Brain System Supporting Allostasis and Interoception in Humans. Nat Hum Behav 1. Article 0069. https://doi.org/10.1038/s41562-017-0069
- 41.Vandervelde A, Miller H, Younts J (2014) Impact on medicare payments of shift in site of care for chemotherapy administration. Berkeley Research Group. https://www.communityoncology.org/UserFiles/BRG_340B_SiteofCare_ReportF_6-9-14.pdf
- 42.McCrary JM, Goldstein D, Boyle F, Cox K, Grimison P, Kiernan MC, Krishnan AV, Lewis CR, Webber K, Baron-Hay S, Horvath L, Park SB, I.F.D.w. party (2017) Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer 25:3485. https://doi.org/10.1007/s00520-017-3772-y
- 44.Gewandter JS, Freeman R, Kitt RA, Cavaletti G, Gauthier LR, McDermott MP, Mohile NA, Mohlie SG, Smith AG, Tejani MA, Turk DC, Dworkin RH (2017) Chemotherapy-induced peripheral neuropathy clinical trials: review and recommendations. Neurology 89(8):859–869. https://doi.org/10.1212/WNL.0000000000004272 CrossRefPubMedGoogle Scholar